Cel Sci (CVM) Cash from Operations (2010 - 2026)
Cel Sci (CVM) posted Cash from Operations of 4022389.0 for Q1 2026, little changed sequentially from 4022105.0 in Q4 2025, and up 7.95% YoY from 3726310.64 in Q1 2025.
Cel Sci (CVM) Cash from Operations (2010 - 2026) Analysis & Trends
Cel Sci has reported Cash from Operations for 16 years, with the latest figure at 4022389.0 in Q1 2026.
- Quarterly Cash from Operations rose 7.95% year-over-year to 4022389.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16654679.0 (up 6.98% YoY) and the FY2025 annual result came in at 17119737.0, up 8.99% from the prior year.
- Cash from Operations held at 4022389.0 in Q1 2026 per CVM's latest filing, from 4022105.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2731662.0 in Q1 2022 and troughed at 7471171.0 in Q1 2023.
- A 5-year average of 4721117.82 and a median of 4666649.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2023: Cash from Operations surged 44.89% in 2022, then slumped 173.5% in 2023.
- Over 5 years, Cash from Operations stood at 4666649.0 in 2022, then retreated by 4.74% to 4887928.0 in 2023, then grew by 15.3% to 4139973.0 in 2024, then rose by 2.85% to 4022105.0 in 2025, then dropped by 0.01% to 4022389.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 4022389.0, 4022105.0, and 4670523.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Cel Sci | 2.12 Mn | -4.42 Mn | - | -4.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.02 Mn |
| Mar 31, 2026 | -4.02 Mn |
| Dec 31, 2025 | -4.02 Mn |
| Dec 31, 2025 | -4.02 Mn |
| Sep 30, 2025 | -4.67 Mn |
| Sep 30, 2025 | -4.67 Mn |
| Jun 30, 2025 | -3.94 Mn |
| Jun 30, 2025 | -3.94 Mn |
| Mar 31, 2025 | -4.37 Mn |
| Mar 31, 2025 | -4.37 Mn |
| Dec 31, 2024 | -4.14 Mn |
| Dec 31, 2024 | -4.14 Mn |
| Sep 30, 2024 | -4.82 Mn |
| Sep 30, 2024 | -4.82 Mn |
| Jun 30, 2024 | -4.58 Mn |
| Jun 30, 2024 | -4.58 Mn |
| Mar 31, 2024 | -4.53 Mn |
| Mar 31, 2024 | -4.53 Mn |
| Dec 31, 2023 | -4.89 Mn |
| Dec 31, 2023 | -4.89 Mn |